Efficacy of a novel chewable tablet (Credelio Quattro™) containing lotilaner, moxidectin, praziquantel, and pyrantel against Toxocara canis and Toxascaris leonina infections in dogs [PDF]
Background Roundworms such as Toxascaris leonina and Toxocara canis are routinely diagnosed in dogs globally, especially in dogs 6 months of age or younger.
Samuel Charles +7 more
doaj +3 more sources
Efficacy of lotilaner (Credelio™), a novel oral isoxazoline against naturally occurring mange mite infestations in dogs caused by Demodex spp. [PDF]
Background The oral systemic efficacy of lotilaner (Credelio™, Elanco) was evaluated against Demodex spp. in naturally infested dogs with generalized demodicosis.
Daniel E. Snyder +2 more
doaj +3 more sources
A randomized, controlled field study to assess the efficacy and safety of lotilaner flavored chewable tablets (Credelio™) in eliminating fleas in client-owned dogs in the USA [PDF]
Background Preclinical studies have shown that the novel isoxazoline, lotilaner (Credelio™, Elanco) administered orally to dogs, produces rapid flea and tick knockdown and sustained speed of kill for at least a month post-treatment with a wide safety ...
Daniela Karadzovska +7 more
doaj +4 more sources
Assessment of the speed of flea kill of lotilaner (Credelio™) throughout the month following oral administration to dogs [PDF]
Background Lotilaner (Credelio™, Elanco), a novel isoxazoline, is a systemic insecticide and acaricide that is rapidly absorbed following oral administration to dogs and has a half-life of 30 days.
Daniela Cavalleri +4 more
doaj +3 more sources
Laboratory evaluation of the speed of kill of lotilaner (Credelio™) against Ixodes ricinus ticks on dogs [PDF]
Background With the geographical expansion of tick species and increased recognition of pathogens they transmit, there is a requirement for safe and rapidly effective control measures for dogs.
Martin Murphy +4 more
doaj +3 more sources
Comparative speed of kill of induced Ixodes scapularis infestations following treatment of dogs with endectocides containing either sarolaner (Simparica Trio™), afoxolaner (NexGard® PLUS), or lotilaner (Credelio Quattro™) [PDF]
Background Ixodes scapularis is a consequential tick species in North America that can transmit multiple pathogens of canine and public health significance. Acaricidal speed is critical for reducing the risk of pathogen transmission.
Kathryn E. Reif +13 more
doaj +3 more sources
A randomized, controlled study to assess the efficacy and safety of lotilaner (Credelio™) in controlling ticks in client-owned dogs in Europe [PDF]
Background Oral administration of lotilaner flavoured chewable tablets (Credelio™, Elanco) to dogs has been shown to provide a rapid onset of killing activity of infesting ticks, with sustained efficacy for at least 35 days.
Daniela Cavalleri +4 more
doaj +3 more sources
The novel isoxazoline ectoparasiticide lotilaner (Credelio™): a non-competitive antagonist specific to invertebrates γ-aminobutyric acid-gated chloride channels (GABACls) [PDF]
Background The isoxazolines are a novel class of parasiticides that are potent inhibitors of γ-aminobutyric acid (GABA)-gated chloride channels (GABACls) and, to a lesser extent, of inhibitory glutamate-gated chloride channels (GluCls).
Lucien Rufener +3 more
doaj +3 more sources
Laboratory evaluations of the immediate and sustained effectiveness of lotilaner (Credelio™) against three common species of ticks affecting dogs in Europe [PDF]
Background There is a continuing need for novel approaches to tick control in dogs. One such approach lies in the ability of lotilaner (Credelio™), an isoxazoline with a rapid onset of action, to provide sustained efficacy against ticks. Two studies were
Daniela Cavalleri +5 more
doaj +3 more sources
Two randomized, controlled studies to assess the efficacy and safety of lotilaner (Credelio™) in preventing Dermacentor reticulatus transmission of Babesia canis to dogs [PDF]
Background Dogs worldwide are at risk of Babesia spp. infections. Preventive efficacy of lotilaner tablets (Credelio™, Elanco) against Babesia canis was evaluated in two studies.
Daniela Cavalleri +4 more
doaj +3 more sources

